Can an oral pill boost muscle strength in pompe disease?

NCT ID NCT07750990

Not yet recruiting Disease control Sponsor: Shionogi Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study tests the long-term safety and effectiveness of an experimental oral drug called S-606001 in adults with late-onset Pompe disease, a genetic condition that causes progressive muscle weakness. Participants who completed a prior S-606001 study can join, and they will receive S-606001 alongside their standard enzyme replacement therapy. Researchers will track side effects and measure changes in breathing, walking ability, and daily activities over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
S-606001, an oral drug, plus standard enzyme replacement therapy (ERT) given intravenously
What this could lead to
If successful, this could support S-606001 as a long-term add-on treatment to improve muscle function and daily living in people with late-onset Pompe disease.
What could go wrong
This is an early-phase extension study with a small number of participants, so long-term benefits are uncertain. Possible side effects and the need for continued ERT remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LATE-ONSET POMPE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.